Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Variagenics board turns down rival bid:

This article was originally published in Clinica

Executive Summary

The board of directors of Variagenics, the molecular diagnostics firm that has agreed to a merger with biotech firm Hyseq Pharmaceuticals, has expressed its opposition to a rival bid. Acacia Research Corporation, a company which invests in technology and life science businesses, is offering a stock-for-stock deal under which it proposed to integrate Variagenics into its CombiMatrix life science biochip subsidiary. Variagenics' directors believe that the future business model with Hyseq as a biotherapeutic/diagnostic product company has more potential than CombiMatrix's research tool focus.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT060858

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel